홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
AVBP
#2111
ArriVent BioPharma, Inc. Common Stock
22.9
7
+0.22%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+0.22%
월간 변동
-1.20%
6달 변화
+19.57%
년간 변동율
-4.01%
이전 종가
22.9
2
Open
22.9
3
Bid
Ask
Low
22.9
3
High
22.9
7
양
76
마켓
주식
헬스케어
AVBP
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2024
TTM
Key stats
Total common shares outstanding
34.02 M
—
Valuation ratios
Enterprise value
831.9 M
2.83 B
Price to earnings ratio
-10.41
-25.11
Price to sales ratio
—
—
Price to cash flow ratio
11.94
27.39
Price to book ratio
3.25
5.23
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
0.29
0.6
Return on equity %
0.31
0.64
Return on invested capital %
962.92
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
13.14
55.12
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
2.23
4.12
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
6.95
21.45
Net current asset value per share
7.21
27.5
Tangible book value per share
8.19
28.58
Working capital per share
6.66
25.5
Book value per share
8.19
28.58
뉴스
Cantor Fitzgerald reitera calificación de Mejor Rendimiento para acciones de ArriVent
Cantor Fitzgerald reitera calificación de Sobreponderación para ArriVent
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Oppenheimer reitera calificación de Mejor Rendimiento para acciones de ArriVent BioPharma
Oppenheimer reitera calificación de Outperform para acciones de ArriVent BioPharma
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Cantor Fitzgerald inicia cobertura de ArriVent BioPharma con calificación de Sobreponderación
Cantor Fitzgerald inicia cobertura de ArriVent BioPharma con calificación Overweight
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
ArriVent administra el primer paciente en ensayo pivotal fase 3 para fármaco contra cáncer de pulmón